Journal
VIRUSES-BASEL
Volume 2, Issue 6, Pages 1279-1305Publisher
MDPI
DOI: 10.3390/v2061279
Keywords
antiviral therapy; HBV therapy; nucleoside analogs; viral hepatitis
Categories
Funding
- VIRGIL European Network of Excellence on Antiviral Drug Resistance [LSHM-CT-2004-503359]
- FWO [G.0267.04]
Ask authors/readers for more resources
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available